The Current Ratio as of December 2024 (TTM) for Verona Pharma plc (VRNA) is 13.03

According to Verona Pharma plc’s latest financial reports and current stock price. The company's current Current Ratio is 13.03. This represents a change of -28.95% compared to the average of 18.34 of the last 4 quarters.

Verona Pharma plc (VRNA) Historical Current Ratio (quarterly & annually)

How has VRNA Current Ratio performed in the past?

The mean historical Current Ratio of Verona Pharma plc over the last ten years is 11.54. The current 13.03 Current Ratio has changed 11.19% with respect to the historical average. Over the past ten years (40 quarters), VRNA's Current Ratio was at its highest in in the December 2023 quarter at 33.33. The Current Ratio was at its lowest in in the September 2016 quarter at 0.

Verona Pharma plc (VRNA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Verona Pharma plc Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Verona Pharma plc (VRNA) Average Current Ratio

How has VRNA Current Ratio performed in the past?

The current Current Ratio of Verona Pharma plc (VRNA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Verona Pharma plc (VRNA) Current Ratio vs. Peers

How is VRNA’s Current Ratio compared to its peers?

Verona Pharma plc’s Current Ratio is less than Ventyx Biosciences, Inc. (23.52), less than IDEAYA Biosciences, Inc. (22.93), greater than Protagonist Therapeutics, Inc. (10.70), greater than Syndax Pharmaceuticals, Inc. (6.99), less than Day One Biopharmaceuticals, Inc. (14.62), greater than X4 Pharmaceuticals, Inc. (4.89), greater than Inozyme Pharma, Inc. (7.68), greater than Acumen Pharmaceuticals, Inc. (10.43), greater than Mereo BioPharma Group plc (6.10), less than Terns Pharmaceuticals, Inc. (32.99), greater than Amylyx Pharmaceuticals, Inc. (4.55), less than MoonLake Immunotherapeutics (25.51), greater than Mirati Therapeutics, Inc. (7.54), greater than Apellis Pharmaceuticals, Inc. (4.36), less than Akero Therapeutics, Inc. (17.25), greater than Madrigal Pharmaceuticals, Inc. (5.98), less than Viking Therapeutics, Inc. (36.47),

Build a custom stock screener for Verona Pharma plc (VRNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verona Pharma plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Verona Pharma plc (VRNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Verona Pharma plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.